Comparison

PAI-1 Recombinant Protein

Item no. PRS-40-126-0.002mg
Manufacturer ProSci
Amount 0.002 mg
Quantity options 0.002 mg 0.01 mg
Category
Type Proteins Recombinant
Format Lyophilized
Specific against other
Purity Greater than 98% by SDS-PAGE gel and HPLC analyses.<br><br>Endotoxin level is less than 0.1 ng per μg (1EU/μg).
Sequence MVHHPPSYVA HLASDFGVRV FQQVAQASKD RNVVFSPYGV ASVLAMLQLT TGGETQQQIQ AAMGFKIDDK GMAPALRHLY KELMGPWNKD EISTTDAIFV QRDLKLVQGF MPHFFRLFRS TVKQVDFSEV ERARFIINDW VKTHTKGMIS NLLGKGAVDQ LTRLVLVNAL YFNGQWKTPF PDSSTHRRLF HKSDGSTVSV PMMAQTNKFN YTEFTTPDGH YYDILELPYH GD
NCBI SERPINE1
ECLASS 10.1 32160409
ECLASS 11.0 32160409
UNSPSC 12352202
Alias PAI, PAI1, PAI-1, PLANH1, Plasminogen activator inhibitor 1, Endothelial plasminogen activator inhibitor, PAI
Available
Storage Conditions
The lyophilized PAI-1 recombinant protein is stable for at least 2 years from date of receipt at -20°C. Reconstituted PAI-1 is stable for at least 3 months when stored in working aliquots with a carrier protein at -20°C. As with any protein, exposing PAI-1 recombinant protein to repeated freeze / thaw cycles is not recommended. When working with proteins care should be taken to keep recombinant protein at a cool and stable temperature.
Biological Activity
Determined by its inhibitory effect against single chain tPA induced cleavage of a chromogenic substrate in Imidazole Buffer at 37°C. Half maximal inhibition against 1.0 μg/mL of single chain tPA was obtained at a concentration of 2.0 μg/mL.
Background
Plasminogen Activator Inhibitor-1 (PAI-1, Serpin E1) is a member of the serpin family of serine protease inhibitors, and is the primary inhibitor of urokinase and tissue plasminogen activator (tPA). PAI-1 is expressed predominantly in adipose, liver and vascular tissues, and is also produced by certain tumor cells. Elevated levels of PAI-1 are associated with obesity, diabetes and cardiovascular disease, and increased production of PAI-1 is induced by various obesity related factors such as TNFα , glucose, insulin, and very-low-density lipoprotein. The obesity related elevation of PAI-1 levels along with the consequential deficiency in plasminogen activators can lead directly to increased risk of thrombosis and other coronary diseases. Accordingly, PAI-1 has been implicated as an important molecular link between obesity and coronary disease. PAI-1 can also specifically bind vitronectin (VTN) to form a stable active complex with an increased circulatory half life relative to free PAI-1. Recombinant human PAI-1 is a 42.7 kDa protein containing 379 amino acid residues.
Protein Gi #
10835159
NCBI Official Name
serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1
NCBI Organism
Homo sapiens
Disclaimer
This product is for research use only.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 0.002 mg
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close